Sun Pharma’s Two US Arms to Pay $85 Mn in Settlement Pacts over Antritrust Litigation
“Sun Pharma Ltd today informed the stock exchanges that its two US-based subsidiaries have signed settlement agreements in generic pharmaceuticals pricing antitrust litigation. The two units have signed settlement agreements with the Direct Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing,” reports Mint in their blog.
“Under the terms of the settlement agreements, the subsidiaries will make an aggregate payment amounting to a combined total of $85 million in exchange for a full release of all claims asserted against them. The settlement payment amounts will be reduced by $10 million if the direct purchasers that opt out of the putative class.”
